{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T01:06:47Z","timestamp":1780621607399,"version":"3.54.1"},"reference-count":71,"publisher":"Walter de Gruyter GmbH","issue":"5","funder":[{"name":"Innovation Foundation of Jinan Clinical Medicine Science and Technology","award":["2024304002"],"award-info":[{"award-number":["2024304002"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,5,26]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Due to the condition itself and long-term glucocorticoid medication, children with congenital adrenal hyperplasia (CAH) frequently experience secondary impairment of adult height. Recombinant human growth hormone (rhGH) has been tried to improve growth outcomes either by itself or in conjunction with gonadotropin-releasing hormone analogs; however, there is currently insufficient evidence to support its safety and effectiveness. Six clinical trials in this area are thoroughly reviewed in this article, which highlights the fact that the majority of the evidence currently available comes from small-sample, nonblinded designs. Although rhGH can improve projected or ultimate adult height in the near term, long-term metabolic and tumor concerns are still understood. The ambiguity of treatment indications, the significant financial burden, and the uncertainty surrounding long-term safety are the three main practical inconsistencies in the therapeutic application of rhGH that are examined in this paper. A monitoring index framework including growth and development, endocrine metabolism, and systemic safety is suggested based on this information as well as prior research and clinical experience. This article concludes by emphasizing the need for future large-scale prospective studies and patient registration systems to elucidate the risk\u2013benefit ratio of rhGH in various CAH populations and to pay attention to the potential growth-improving effects of novel therapies represented by CRF1 receptor antagonists. The purpose of this article is to give doctors evidence-based, contradiction-aware, and safety-focused decision-making references for controlling the height of CAH children with\u00a0rhGH.<\/jats:p>","DOI":"10.1515\/jpem-2026-0058","type":"journal-article","created":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T06:09:23Z","timestamp":1777874963000},"page":"415-424","source":"Crossref","is-referenced-by-count":0,"title":["Clinical evidence, practical contradictions, and monitoring of rhGH-assisted height enhancement in children with CAH"],"prefix":"10.1515","volume":"39","author":[{"given":"Ying","family":"Zhao","sequence":"first","affiliation":[{"name":"518873 Shandong First Medical University , Jinan , China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jialin","family":"Mu","sequence":"additional","affiliation":[{"name":"Jinan Maternity and Child Care Hospital Affiliated to Shandong First Medical University , Jinan , China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Zou","sequence":"additional","affiliation":[{"name":"518873 Shandong First Medical University , Jinan , China"},{"name":"Jinan Maternity and Child Care Hospital Affiliated to Shandong First Medical University , Jinan , China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"374","published-online":{"date-parts":[[2026,5,4]]},"reference":[{"key":"2026060500564550076_j_jpem-2026-0058_ref_001","doi-asserted-by":"crossref","unstructured":"Auer, MK, Nordenstr\u00f6m, A, Lajic, S, Reisch, N. Congenital adrenal hyperplasia. Lancet 2023;401:227\u201344. https:\/\/doi.org\/10.1016\/s0140-6736(22)01330-7.","DOI":"10.1016\/S0140-6736(22)01330-7"},{"key":"2026060500564550076_j_jpem-2026-0058_ref_002","doi-asserted-by":"crossref","unstructured":"Speiser, PW, Arlt, W, Auchus, RJ, Baskin, LS, Conway, GS, Merke, DP, et al.. Congenital adrenal hyperplasia due to steroid 21-Hydroxylase deficiency: an endocrine society clinical practice guideline. J\u00a0Clin Endocrinol Metab 2018;103:4043\u201388. https:\/\/doi.org\/10.1210\/jc.2018-01865.","DOI":"10.1210\/jc.2018-01865"},{"key":"2026060500564550076_j_jpem-2026-0058_ref_003","doi-asserted-by":"crossref","unstructured":"Merke, DP, Auchus, RJ. Congenital adrenal hyperplasia due to 21-Hydroxylase deficiency. N\u00a0Engl J Med 2020;383:1248\u201361. https:\/\/doi.org\/10.1056\/nejmra1909786.","DOI":"10.1056\/NEJMra1909786"},{"key":"2026060500564550076_j_jpem-2026-0058_ref_004","doi-asserted-by":"crossref","unstructured":"Nokoff, NJ, Buchanan, C, Barker, JM. Clinical manifestations and treatment challenges in infants and children with classic congenital adrenal hyperplasia due to 21-Hydroxylase deficiency. J\u00a0Clin Endocrinol Metab 2025;110:S13\u201324. https:\/\/doi.org\/10.1210\/clinem\/dgae563.","DOI":"10.1210\/clinem\/dgae563"},{"key":"2026060500564550076_j_jpem-2026-0058_ref_005","doi-asserted-by":"crossref","unstructured":"Claahsen-van Der Grinten, HL, Speiser, PW, Ahmed, SF, Arlt, W, Auchus, RJ, Falhammar, H, et al.. Congenital adrenal hyperplasia-current insights in pathophysiology, diagnostics, and management. Endocr Rev 2022;43:91\u2013159. https:\/\/doi.org\/10.1210\/endrev\/bnab016.","DOI":"10.1210\/endrev\/bnab016"},{"key":"2026060500564550076_j_jpem-2026-0058_ref_006","doi-asserted-by":"crossref","unstructured":"Mooij, CF, Webb, EA, Claahsen Van Der Grinten, HL, Krone, N. Cardiovascular health, growth and gonadal function in children and adolescents with congenital adrenal hyperplasia. Arch Dis Child 2017;102:578\u201384. https:\/\/doi.org\/10.1136\/archdischild-2016-311910.","DOI":"10.1136\/archdischild-2016-311910"},{"key":"2026060500564550076_j_jpem-2026-0058_ref_007","doi-asserted-by":"crossref","unstructured":"Muthusamy, K, Elamin, MB, Smushkin, G, Murad, MH, Lampropulos, JF, Elamin, KB, et al.. Clinical review: adult height in patients with congenital adrenal hyperplasia: a systematic review and metaanalysis. J\u00a0Clin Endocrinol Metab 2010;95:4161\u201372. https:\/\/doi.org\/10.1210\/jc.2009-2616.","DOI":"10.1210\/jc.2009-2616"},{"key":"2026060500564550076_j_jpem-2026-0058_ref_008","doi-asserted-by":"crossref","unstructured":"Prete, A, Auchus, RJ, Ross, RJ. Clinical advances in the pharmacotherapy of congenital adrenal hyperplasia. Eur J Endocrinol 2021;186:R1\u201314. https:\/\/doi.org\/10.1530\/eje-21-0794.","DOI":"10.1530\/EJE-21-0794"},{"key":"2026060500564550076_j_jpem-2026-0058_ref_009","doi-asserted-by":"crossref","unstructured":"Ustyol, A, Eugster, EA. Clinical variability in congenital adrenal hyperplasia: a distinct subgroup with a low glucocorticoid dose requirement. Horm Res Paediatr 2025:1\u20135. https:\/\/doi.org\/10.1159\/000546883.","DOI":"10.1159\/000546883"},{"key":"2026060500564550076_j_jpem-2026-0058_ref_010","doi-asserted-by":"crossref","unstructured":"Ng, SM, Stepien, KM, Krishan, A. Glucocorticoid replacement regimens for treating congenital adrenal hyperplasia. Cochrane Database Syst Rev 2020;3:CD012517. https:\/\/doi.org\/10.1002\/14651858.CD012517.pub2.","DOI":"10.1002\/14651858.CD012517.pub2"},{"key":"2026060500564550076_j_jpem-2026-0058_ref_013","doi-asserted-by":"crossref","unstructured":"Lin-Su, K, Harbison, MD, Lekarev, O, Vogiatzi, MG, New, MI. Final adult height in children with congenital adrenal hyperplasia treated with growth hormone. J\u00a0Clin Endocrinol Metab 2011;96:1710\u20137. https:\/\/doi.org\/10.1210\/jc.2010-2699.","DOI":"10.1210\/jc.2010-2699"},{"key":"2026060500564550076_j_jpem-2026-0058_ref_015","doi-asserted-by":"crossref","unstructured":"Lin-Su, K, Vogiatzi, MG, Marshall, I, Harbison, MD, Macapagal, MC, Betensky, B, et al.. Treatment with growth hormone and luteinizing hormone releasing hormone analog improves final adult height in children with congenital adrenal hyperplasia. J\u00a0Clin Endocrinol Metab 2005;90:3318\u201325. https:\/\/doi.org\/10.1210\/jc.2004-2128.","DOI":"10.1210\/jc.2004-2128"},{"key":"2026060500564550076_j_jpem-2026-0058_ref_016","doi-asserted-by":"crossref","unstructured":"Quintos, JB, Vogiatzi, MG, Harbison, MD, New, MI. Growth hormone therapy alone or in combination with gonadotropin-releasing hormone analog therapy to improve the height deficit in children with congenital adrenal hyperplasia. J\u00a0Clin Endocrinol Metab 2001;86:1511\u20137. https:\/\/doi.org\/10.1210\/jcem.86.4.7412.","DOI":"10.1210\/jc.86.4.1511"},{"key":"2026060500564550076_j_jpem-2026-0058_ref_012","doi-asserted-by":"crossref","unstructured":"Longui, CA, Kochi, C, Calliari, LEP, Modkovski, MBR, Soares, M, Alves, EF, et al.. Near-final height in patients with congenital adrenal hyperplasia treated with combined therapy using GH and GnRHa. Arq Bras Endocrinol Metabol 2011;55:661\u20134. https:\/\/doi.org\/10.1590\/s0004-27302011000800023.","DOI":"10.1590\/S0004-27302011000800023"},{"key":"2026060500564550076_j_jpem-2026-0058_ref_014","doi-asserted-by":"crossref","unstructured":"Harbison, MD, Lin-Su, K, New, MI. Growth hormone treatment in children with congenital adrenal hyperplasia. Adv Exp Med Biol 2011;707:107.","DOI":"10.1007\/978-1-4419-8002-1_23"},{"key":"2026060500564550076_j_jpem-2026-0058_ref_011","doi-asserted-by":"crossref","unstructured":"Liu, X, Liu, F, Qi, Y, Han, X, Ma, S, Zheng, R, et al.. Combination therapy of GnRHa, RhGH and anastrozole to improve final adult height deficit in CAH children with CPP. BMC Pediatr 2025;25:362. https:\/\/doi.org\/10.1186\/s12887-025-05703-8.","DOI":"10.1186\/s12887-025-05703-8"},{"key":"2026060500564550076_j_jpem-2026-0058_ref_017","unstructured":"Tar\u0131m, O. Height predictions by bayley-pinneau method may misguide pediatric endocrinologists. Turk J Pediatr 2013;55:485\u201392."},{"key":"2026060500564550076_j_jpem-2026-0058_ref_018","doi-asserted-by":"crossref","unstructured":"Badawi, N, Fawaz, L, Amin, A, Kamel, A, Arafa, N. The validity of the bayley-pinneau method in predicting final adult height at the onset of puberty in patients with classic congenital adrenal hyperplasia. Endokrynol Pol 2021;72:301\u20137. https:\/\/doi.org\/10.5603\/ep.a2021.0039.","DOI":"10.5603\/EP.a2021.0039"},{"key":"2026060500564550076_j_jpem-2026-0058_ref_019","doi-asserted-by":"crossref","unstructured":"G\u00fcven, A, Nurcan Cebeci, A, Hancili, S. Gonadotropin releasing hormone analog treatment in children with congenital adrenal hyperplasia complicated by central precocious puberty. Hormones (Basel) 2015;14:265\u201371. https:\/\/doi.org\/10.14310\/horm.2002.1555.","DOI":"10.14310\/horm.2002.1555"},{"key":"2026060500564550076_j_jpem-2026-0058_ref_020","doi-asserted-by":"crossref","unstructured":"Shi, Y, Ma, Z, Yang, X, Ying, Y, Luo, X, Hou, L, et al.. Gonadotropin-releasing hormone analogue and recombinant human growth hormone treatment for idiopathic central precocious puberty in girls. Front Endocrinol 2022;13:1085385. https:\/\/doi.org\/10.3389\/fendo.2022.1085385.","DOI":"10.3389\/fendo.2022.1085385"},{"key":"2026060500564550076_j_jpem-2026-0058_ref_021","unstructured":"Lu, XY, Zhao, Y, Jin, Y, Yang, CW, Song, QL. A comparative study of three different height prediction methods in girls with precocious puberty of phlegm-dampness obstruction type treated by Jianpi Ziyin prescription. Chin J. Integr Tradit West Pediatr 2023;15:339. (in Chinese)"},{"key":"2026060500564550076_j_jpem-2026-0058_ref_022","doi-asserted-by":"crossref","unstructured":"Lee, JM, Davis, MM, Clark, SJ, Hofer, TP, Kemper, AR. Estimated cost-effectiveness of growth hormone therapy for idiopathic short stature. Arch Pediatr Adolesc Med 2006;160:263\u20139. https:\/\/doi.org\/10.1001\/archpedi.160.3.263.","DOI":"10.1001\/archpedi.160.3.263"},{"key":"2026060500564550076_j_jpem-2026-0058_ref_023","unstructured":"Pakdaman, M, Golmakani, F, Dehghan, HR, Valagohar, R, Yazdi, A, Namayande, M, et al.. The cost-effectiveness of growth hormone and its consumption indications: a systematic review of economic evaluation studies. Health Technology Assessment in Action 2019;3."},{"key":"2026060500564550076_j_jpem-2026-0058_ref_024","doi-asserted-by":"crossref","unstructured":"Merino, M, Tornero-Aguilera, JF, Rubio-Zarapuz, A, Villanueva-Tobaldo, CV, Mart\u00edn-Rodr\u00edguez, A, Clemente-Su\u00e1rez, VJ, et al.. Body perceptions and psychological well-being: a review of the impact of social media and physical measurements on self-esteem and mental health with a focus on body image satisfaction and its relationship with cultural and gender factors. Healthcare (Basel) 2024;12. https:\/\/doi.org\/10.3390\/healthcare12141396.","DOI":"10.3390\/healthcare12141396"},{"key":"2026060500564550076_j_jpem-2026-0058_ref_025","doi-asserted-by":"crossref","unstructured":"Silvers, JB, Marinova, D, Mercer, MB, Connors, A, Cuttler, L. A national study of physician recommendations to initiate and discontinue growth hormone for short stature. Pediatrics 2010;126:468\u201376. https:\/\/doi.org\/10.1542\/peds.2009-3609.","DOI":"10.1542\/peds.2009-3609"},{"key":"2026060500564550076_j_jpem-2026-0058_ref_026","doi-asserted-by":"crossref","unstructured":"Finkelstein, BS, Silvers, JB, Marrero, U, Neuhauser, D, Cuttler, L. Insurance coverage, physician recommendations, and access to emerging treatments: growth hormone therapy for childhood short stature. JAMA 1998;279:663\u20138. https:\/\/doi.org\/10.1001\/jama.279.9.663.","DOI":"10.1001\/jama.279.9.663"},{"key":"2026060500564550076_j_jpem-2026-0058_ref_027","doi-asserted-by":"crossref","unstructured":"Grimberg, A, Kanter, GP. US growth hormone use in the idiopathic short stature era: trends in insurer payments and patient financial burden. J\u00a0Endocr Soc 2019;3:2023\u201331. https:\/\/doi.org\/10.1210\/js.2019-00246.","DOI":"10.1210\/js.2019-00246"},{"key":"2026060500564550076_j_jpem-2026-0058_ref_028","unstructured":"Martel-Duguech, LM, Jorgensen, JOL, Korbonits, M, Johannsson, G, Webb, SM, Amadidou, F, et al.. ESE audit on management of adult growth hormone deficiency in clinical practice. Eur J Endocrinol 2020. https:\/\/doi.org\/10.1530\/EJE-20-1180IF."},{"key":"2026060500564550076_j_jpem-2026-0058_ref_029","doi-asserted-by":"crossref","unstructured":"Barbot, M, Mazzeo, P, Lazzara, M, Ceccato, F, Scaroni, C. Metabolic syndrome and cardiovascular morbidity in patients with congenital adrenal hyperplasia. Front Endocrinol 2022;13:934675. https:\/\/doi.org\/10.3389\/fendo.2022.934675.","DOI":"10.3389\/fendo.2022.934675"},{"key":"2026060500564550076_j_jpem-2026-0058_ref_030","doi-asserted-by":"crossref","unstructured":"Vijayan, R, Bhavani, N, Pavithran, PV, Nair, V, Menon, UV, Menon, AS, et al.. Metabolic profile, cardiovascular risk factors and health-related quality of life in children, adolescents and young adults with congenital adrenal hyperplasia. J\u00a0Pediatr Endocrinol Metab 2019;32:871\u20137. https:\/\/doi.org\/10.1515\/jpem-2019-0079.","DOI":"10.1515\/jpem-2019-0079"},{"key":"2026060500564550076_j_jpem-2026-0058_ref_031","doi-asserted-by":"crossref","unstructured":"Tschaidse, L, Quitter, F, H\u00fcbner, A, Reisch, N. [Long-term morbidity in congenital adrenal hyperplasia]. Internist (Berl) 2022;63:43\u201350. https:\/\/doi.org\/10.1007\/s00108-021-01223-6.","DOI":"10.1007\/s00108-021-01223-6"},{"key":"2026060500564550076_j_jpem-2026-0058_ref_032","doi-asserted-by":"crossref","unstructured":"Perry, JK, Wu, Z, Mertani, HC, Zhu, T, Lobie, PE. Tumour-derived human growth hormone as a therapeutic target in oncology. Trends Endocrinol Metab 2017;28:587\u201396. https:\/\/doi.org\/10.1016\/j.tem.2017.05.003.","DOI":"10.1016\/j.tem.2017.05.003"},{"key":"2026060500564550076_j_jpem-2026-0058_ref_033","doi-asserted-by":"crossref","unstructured":"Lu, M, Flanagan, JU, Langley, RJ, Hay, MP, Perry, JK. Targeting growth hormone function: strategies and therapeutic applications. Signal Transduct Target Ther 2019;4:3. https:\/\/doi.org\/10.1038\/s41392-019-0036-y.","DOI":"10.1038\/s41392-019-0036-y"},{"key":"2026060500564550076_j_jpem-2026-0058_ref_034","doi-asserted-by":"crossref","unstructured":"Werner, H, Laron, Z. Role of the GH-IGF1 system in progression of cancer. Mol Cell Endocrinol 2020;518:111003. https:\/\/doi.org\/10.1016\/j.mce.2020.111003.","DOI":"10.1016\/j.mce.2020.111003"},{"key":"2026060500564550076_j_jpem-2026-0058_ref_035","doi-asserted-by":"crossref","unstructured":"Basu, R, Kopchick, JJ. The effects of growth hormone on therapy resistance in cancer. Cancer Drug Resist 2019;2:827\u201346. https:\/\/doi.org\/10.20517\/cdr.2019.27.","DOI":"10.20517\/cdr.2019.27"},{"key":"2026060500564550076_j_jpem-2026-0058_ref_036","doi-asserted-by":"crossref","unstructured":"Boguszewski, MCS, Boguszewski, CL, Chemaitilly, W, Cohen, LE, Gebauer, J, Higham, C, et al.. Safety of growth hormone replacement in survivors of cancer and intracranial and pituitary tumours: a consensus statement. Eur J Endocrinol 2022;186:P35\u20132. https:\/\/doi.org\/10.1530\/eje-21-1186.","DOI":"10.1530\/EJE-21-1186"},{"key":"2026060500564550076_j_jpem-2026-0058_ref_037","doi-asserted-by":"crossref","unstructured":"Raman, S, Grimberg, A, Waguespack, SG, Miller, BS, Sklar, CA, Meacham, LR, et al.. Risk of neoplasia in pediatric patients receiving growth hormone Therapy\u00a0\u2013\u00a0A report from the pediatric endocrine society drug and therapeutics committee. J\u00a0Clin Endocrinol Metab 2015;100:2192\u2013203. https:\/\/doi.org\/10.1210\/jc.2015-1002.","DOI":"10.1210\/jc.2015-1002"},{"key":"2026060500564550076_j_jpem-2026-0058_ref_038","doi-asserted-by":"crossref","unstructured":"Danowitz, M, Grimberg, A. Clinical indications for growth hormone therapy. Adv Pediatr 2022;69:203\u201317. https:\/\/doi.org\/10.1016\/j.yapd.2022.03.005.","DOI":"10.1016\/j.yapd.2022.03.005"},{"key":"2026060500564550076_j_jpem-2026-0058_ref_039","doi-asserted-by":"crossref","unstructured":"Costa, FC, de Sousa, DL, Madureira, G, Mathias, PMBR, Mendonca, BB, Miranda, MC, et al.. RF21 | PSAT93 improvement of final height in congenital adrenal hyperplasia patients treated with recombinant growth hormone. J\u00a0Endocrine Society 2022;6:A138. https:\/\/doi.org\/10.1210\/jendso\/bvac150.281. A138.","DOI":"10.1210\/jendso\/bvac150.281"},{"key":"2026060500564550076_j_jpem-2026-0058_ref_040","doi-asserted-by":"crossref","unstructured":"Sarafoglou, K, Mercado Munoz, Y, Sukin, C, Lteif, A, Kyllo, J, Miller, BS, et al.. The importance of disease specific growth charts for children with congenital adrenal hyperplasia. J\u00a0Clin Endocrinol Metab 2025;111:1125\u201335. https:\/\/doi.org\/10.1210\/clinem\/dgaf554IF.","DOI":"10.1210\/clinem\/dgaf554"},{"key":"2026060500564550076_j_jpem-2026-0058_ref_041","doi-asserted-by":"crossref","unstructured":"Savage, MO. Linear growth in children and adolescents with congenital adrenal hyperplasia. Curr Opin Pediatr 2024;36:463\u20136. https:\/\/doi.org\/10.1097\/mop.0000000000001361.","DOI":"10.1097\/MOP.0000000000001361"},{"key":"2026060500564550076_j_jpem-2026-0058_ref_042","doi-asserted-by":"crossref","unstructured":"Nordenstr\u00f6m, A, Falhammar, H, Lajic, S. Current and novel treatment strategies in children with congenital adrenal hyperplasia. Horm Res Paediatr 2023;96:560\u201372. https:\/\/doi.org\/10.1159\/000522260.","DOI":"10.1159\/000522260"},{"key":"2026060500564550076_j_jpem-2026-0058_ref_043","doi-asserted-by":"crossref","unstructured":"de Arriba Mu\u00f1oz, A, Mu\u00f1iz, VC, Saez, JJA, Beisti, A, Llovet, E, Aizp\u00fan, JIL, et al.. Impact of adherence on growth response during the first 2\u00a0years of growth hormone treatment. Endocrine 2021;72:513\u201323. https:\/\/doi.org\/10.1007\/s12020-020-02560-6.","DOI":"10.1007\/s12020-020-02560-6"},{"key":"2026060500564550076_j_jpem-2026-0058_ref_044","doi-asserted-by":"crossref","unstructured":"Priyanka, R, Subbiah, S. Abstract 29: effect of gonadotropin releasing hormone analog treatment on final adult height in children with congenital adrenal hyperplasia complicated by central precocious puberty. Indian J Endocrinology Metaboli 2022:26.","DOI":"10.4103\/2230-8210.342143"},{"key":"2026060500564550076_j_jpem-2026-0058_ref_045","doi-asserted-by":"crossref","unstructured":"Minnetti, M, Caiulo, S, Ferrigno, R, Baldini-Ferroli, B, Bottaro, G, Gianfrilli, D, et al.. Abnormal linear growth in paediatric adrenal diseases: pathogenesis, prevalence and management. Clin Endocrinol 2020;92:98\u2013108. https:\/\/doi.org\/10.1111\/cen.14131.","DOI":"10.1111\/cen.14131"},{"key":"2026060500564550076_j_jpem-2026-0058_ref_046","doi-asserted-by":"crossref","unstructured":"Bamba, V, Kanakatti Shankar, R. Approach to the patient: safety of growth hormone replacement in children and adolescents. J\u00a0Clin Endocrinol Metab 2022;107:847\u201361. https:\/\/doi.org\/10.1210\/clinem\/dgab746.","DOI":"10.1210\/clinem\/dgab746"},{"key":"2026060500564550076_j_jpem-2026-0058_ref_047","doi-asserted-by":"crossref","unstructured":"He, M, Deng, X, Wang, X, Wan, Y, Huang, J, Zhang, Z, et al.. Association between recombinant growth hormone therapy and all-cause mortality and cancer risk in childhood: systematic review and meta-analysis. Front Pediatr 2022;10:866295. https:\/\/doi.org\/10.3389\/fped.2022.866295.","DOI":"10.3389\/fped.2022.866295"},{"key":"2026060500564550076_j_jpem-2026-0058_ref_048","unstructured":"Sharma, VM. Emerging mechanisms of GH-Induced lipolysis and insulin resistance. Pediatr Endocrinol Rev 2019;17:4\u201316. https:\/\/doi.org\/10.17458\/per.vol17.2019.s.ghlipolysisandinsulinresistance."},{"key":"2026060500564550076_j_jpem-2026-0058_ref_049","doi-asserted-by":"crossref","unstructured":"Sharma, R, Kopchick, JJ, Puri, V, Sharma, VM. Effect of growth hormone on insulin signaling. Mol Cell Endocrinol 2020;518:111038. https:\/\/doi.org\/10.1016\/j.mce.2020.111038.","DOI":"10.1016\/j.mce.2020.111038"},{"key":"2026060500564550076_j_jpem-2026-0058_ref_050","doi-asserted-by":"crossref","unstructured":"M\u00f8ller, N, J\u00f8rgensen, JO, Abildg\u00e5rd, N, Orskov, L, Schmitz, O, Christiansen, JS. Effects of growth hormone on glucose metabolism. Horm Res 1991;36:32\u20135. https:\/\/doi.org\/10.1159\/000182185.","DOI":"10.1159\/000182185"},{"key":"2026060500564550076_j_jpem-2026-0058_ref_051","doi-asserted-by":"crossref","unstructured":"Tamhane, S, Rodriguez-Gutierrez, R, Iqbal, AM, Prokop, LJ, Bancos, I, Speiser, PW, et al.. Cardiovascular and metabolic outcomes in congenital adrenal hyperplasia: a systematic review and meta-analysis. J\u00a0Clin Endocrinol Metab 2018;103:4097\u2013103. https:\/\/doi.org\/10.1210\/jc.2018-01862.","DOI":"10.1210\/jc.2018-01862"},{"key":"2026060500564550076_j_jpem-2026-0058_ref_052","doi-asserted-by":"crossref","unstructured":"Lee, SC, Baranowski, ES, Sakremath, R, Saraff, V, Mohamed, Z. Hypoglycaemia in adrenal insufficiency. Front Endocrinol 2023;14:1198519. https:\/\/doi.org\/10.3389\/fendo.2023.1198519.","DOI":"10.3389\/fendo.2023.1198519"},{"key":"2026060500564550076_j_jpem-2026-0058_ref_053","doi-asserted-by":"crossref","unstructured":"Tavares, MR, Dos Santos, WO, Amaral, AG, List, EO, Kopchick, JJ, Alves, GA, et al.. Growth hormone receptor in VGLUT2 or Sim1 cells regulates glycemia and insulin sensitivity. Proc Natl Acad Sci U S A 2024;121:e2407225121. https:\/\/doi.org\/10.1073\/pnas.2407225121.","DOI":"10.1073\/pnas.2407225121"},{"key":"2026060500564550076_j_jpem-2026-0058_ref_054","doi-asserted-by":"crossref","unstructured":"Bacila, I, Lawrence, NR, Badrinath, SG, Balagamage, C, Krone, NP. Biomarkers in congenital adrenal hyperplasia. Clin Endocrinol 2024;101:300\u201310. https:\/\/doi.org\/10.1111\/cen.14960.","DOI":"10.1111\/cen.14960"},{"key":"2026060500564550076_j_jpem-2026-0058_ref_055","doi-asserted-by":"crossref","unstructured":"Dreves, B, Reznik, Y, Tabarin, A. Congenital adrenal hyperplasia: new biomarkers and adult treatments. Ann Endocrinol 2023;84:472\u201380. https:\/\/doi.org\/10.1016\/j.ando.2023.01.008.","DOI":"10.1016\/j.ando.2023.01.008"},{"key":"2026060500564550076_j_jpem-2026-0058_ref_056","doi-asserted-by":"crossref","unstructured":"Seo, P, Rutter, MM, Yau, M. MON-474 adrenal control in pediatric 11\u03b2-Hydroxylase deficient CAH patients using different hydrocortisone formulations: a two-patient case study. J\u00a0Endocrine Society 2025;9. https:\/\/doi.org\/10.1210\/jendso\/bvaf149.1731.","DOI":"10.1210\/jendso\/bvaf149.1731"},{"key":"2026060500564550076_j_jpem-2026-0058_ref_057","doi-asserted-by":"crossref","unstructured":"Giavoli, C, Profka, E, Rodari, G, Lania, A, Beck-Peccoz, P. Focus on GH deficiency and thyroid function. Best Pract Res Clin Endocrinol Metabol 2017;31:71\u20138. https:\/\/doi.org\/10.1016\/j.beem.2017.02.003.","DOI":"10.1016\/j.beem.2017.02.003"},{"key":"2026060500564550076_j_jpem-2026-0058_ref_058","doi-asserted-by":"crossref","unstructured":"Kubo, T, Furujo, M, Takahashi, K, Hyodo, Y, Tsuchiya, H, Hattori, M, et al.. Effects of growth hormone treatment on lipid profiles. Indian J Pediatr 2018;85:261\u20135. https:\/\/doi.org\/10.1007\/s12098-017-2509-8.","DOI":"10.1007\/s12098-017-2509-8"},{"key":"2026060500564550076_j_jpem-2026-0058_ref_059","doi-asserted-by":"crossref","unstructured":"Foster, C, Burton, A, Scholl, J, Scott, ML, Gunter, V, McCormick, K, et al.. Lipid patterns in treated growth hormone deficient children vs. short stature controls. J\u00a0Pediatr Endocrinol Metab 2014;27:909\u201314. https:\/\/doi.org\/10.1515\/jpem-2013-0488.","DOI":"10.1515\/jpem-2013-0488"},{"key":"2026060500564550076_j_jpem-2026-0058_ref_060","doi-asserted-by":"crossref","unstructured":"Sas, T, Mulder, P, Hokken-Koelega, A. Body composition, blood pressure, and lipid metabolism before and during long-term growth hormone (GH) treatment in children with short stature born small for gestational age either with or without GH deficiency. J\u00a0Clin Endocrinol Metab 2000;85:3786\u201392. https:\/\/doi.org\/10.1210\/jcem.85.10.6917.","DOI":"10.1210\/jc.85.10.3786"},{"key":"2026060500564550076_j_jpem-2026-0058_ref_061","doi-asserted-by":"crossref","unstructured":"Botero, D, Arango, A, Danon, M, Lifshitz, F. Lipid profile in congenital adrenal hyperplasia. Metabolism 2000;49:790\u20133. https:\/\/doi.org\/10.1053\/meta.2000.6261.","DOI":"10.1053\/meta.2000.6261"},{"key":"2026060500564550076_j_jpem-2026-0058_ref_062","doi-asserted-by":"crossref","unstructured":"Bell, J, Parker, KL, Swinford, RD, Hoffman, AR, Maneatis, T, Lippe, B, et al.. Long-term safety of recombinant human growth hormone in children. J\u00a0Clin Endocrinol Metab 2010;95:167\u201377. https:\/\/doi.org\/10.1210\/jc.2009-0178.","DOI":"10.1210\/jc.2009-0178"},{"key":"2026060500564550076_j_jpem-2026-0058_ref_063","doi-asserted-by":"crossref","unstructured":"Darendeliler, F, Karagiannis, G, Wilton, P. Headache, idiopathic intracranial hypertension and slipped capital femoral epiphysis during growth hormone treatment: a safety update from the KIGS database. Horm Res 2007;68:41\u20137. https:\/\/doi.org\/10.1159\/000110474.","DOI":"10.1159\/000110474"},{"key":"2026060500564550076_j_jpem-2026-0058_ref_064","doi-asserted-by":"crossref","unstructured":"Minette, MS, Hoyer, AW, Pham, PP, DeBoer, MD, Reller, MD, Boston, BA, et al.. Cardiac function in congenital adrenal hyperplasia: a pattern\u00a0of\u00a0reversible cardiomyopathy. J\u00a0Pediatr 2013;162:1193\u20138. https:\/\/doi.org\/10.1016\/j.jpeds.2012.11.086. 1198.e1.","DOI":"10.1016\/j.jpeds.2012.11.086"},{"key":"2026060500564550076_j_jpem-2026-0058_ref_065","doi-asserted-by":"crossref","unstructured":"Hofbauer, LC, Compston, JE, Saag, KG, Rauner, M, Tsourdi, E. Glucocorticoid-induced osteoporosis: novel concepts and clinical implications. Lancet Diabetes Endocrinol 2025;13:964\u201379. https:\/\/doi.org\/10.1016\/s2213-8587(25)00251-7.","DOI":"10.1016\/S2213-8587(25)00251-7"},{"key":"2026060500564550076_j_jpem-2026-0058_ref_066","doi-asserted-by":"crossref","unstructured":"Tanaka, Y, Soen, S, Hirata, S, Okada, Y, Fujiwara, S, Tanaka, I, et al.. The 2023 guidelines for the management and treatment of glucocorticoid-induced osteoporosis. J\u00a0Bone Miner Metab 2024;42:143\u201354. https:\/\/doi.org\/10.1007\/s00774-024-01502-w.","DOI":"10.1007\/s00774-024-01502-w"},{"key":"2026060500564550076_j_jpem-2026-0058_ref_067","doi-asserted-by":"crossref","unstructured":"Paccou, J, Yavropoulou, MP, Naciu, AM, Chandran, M, Messina, OD, Rolvien, T, et al.. Prevention and treatment of glucocorticoid-induced osteoporosis in adults: recommendations from the European calcified tissue society. Eur J Endocrinol 2024;191:G1\u201317. https:\/\/doi.org\/10.1093\/ejendo\/lvae146.","DOI":"10.1093\/ejendo\/lvae146"},{"key":"2026060500564550076_j_jpem-2026-0058_ref_068","doi-asserted-by":"crossref","unstructured":"Bolamperti, S, Villa, I, di Filippo, L. Growth hormone and bone: a basic perspective. Pituitary 2024;27:745\u201351. https:\/\/doi.org\/10.1007\/s11102-024-01464-2.","DOI":"10.1007\/s11102-024-01464-2"},{"key":"2026060500564550076_j_jpem-2026-0058_ref_069","doi-asserted-by":"crossref","unstructured":"Tritos, NA, Klibanski, A. Effects of growth hormone on bone. Prog Mol Biol Transl Sci 2016;138:193\u2013211. https:\/\/doi.org\/10.1016\/bs.pmbts.2015.10.008.","DOI":"10.1016\/bs.pmbts.2015.10.008"},{"key":"2026060500564550076_j_jpem-2026-0058_ref_070","doi-asserted-by":"crossref","unstructured":"Lee, A. Crinecerfont: first approval. Drugs 2025;85:839\u201343. https:\/\/doi.org\/10.1007\/s40265-025-02165-1.","DOI":"10.1007\/s40265-025-02165-1"},{"key":"2026060500564550076_j_jpem-2026-0058_ref_071","doi-asserted-by":"crossref","unstructured":"Auchus, RJ, Hamidi, O, Pivonello, R, Bancos, I, Russo, G, Witchel, SF, et al.. Phase 3 trial of crinecerfont in adult congenital adrenal hyperplasia. N\u00a0Engl J Med 2024;391:504\u201314. https:\/\/doi.org\/10.1056\/nejmoa2404656.","DOI":"10.1056\/NEJMoa2404656"}],"container-title":["Journal of Pediatric Endocrinology and Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/jpem-2026-0058\/xml","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/jpem-2026-0058\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T00:58:35Z","timestamp":1780621115000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/jpem-2026-0058\/html"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,1]]},"references-count":71,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2026,3,16]]},"published-print":{"date-parts":[[2026,5,26]]}},"alternative-id":["10.1515\/jpem-2026-0058"],"URL":"https:\/\/doi.org\/10.1515\/jpem-2026-0058","relation":{},"ISSN":["0334-018X","2191-0251"],"issn-type":[{"value":"0334-018X","type":"print"},{"value":"2191-0251","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,1]]}}}